Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OptimizeRx CorpOPRX · Entity 213 | CHIEF FINANCIAL OFFICER | October 05, 2021 | October 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OptimizeRx Corp
Report date October 05, 2021 · Filed October 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (pursuant to 10B5-1 plan)SEC Table I · non-derivative | Direct | 34,796 |
Reported balance
After 2021-10-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-10-05 · Sale · Disposed 4,000 · Balance 34,796 F2: These shares sold pursuant to a plan of disposition adopted on May 11, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| Common Stock (pursuant to 10B5-1 plan)SEC Table I · non-derivative | Direct | 34,796 |
Reported balance
After 2021-10-05 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2021-10-05 · Sale · Disposed 10,000 · Balance 34,796 F1: These shares sold pursuant to a plan of disposition adopted on March 24, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| Common StockSEC Table I · non-derivative | Direct | 44,796 |
Reported balance
After 2021-10-05 transaction · row 2
1 source rowRow 2 · 2021-10-05 · Exercise / conversion · Acquired 10,000 · Balance 44,796 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2025-03-11 | Direct | 34,699 |
Reported balance
After 2021-10-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-10-05 · Exercise / conversion · Disposed 10,000 · Balance 34,699 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares sold pursuant to a plan of disposition adopted on March 24, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: These shares sold pursuant to a plan of disposition adopted on May 11, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2020 Filed Sep 4, 2020 16:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 10,000 | $2.46 | $24,600.00 |
DisclosureSEC source: 0001213900-20-025434 · ownership.xml · nonDerivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 16:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0001213900-20-025434 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,705 F1 · security: These shares sold pursuant to a plan of disposition adopted on June 16, 2020 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 17:15 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 10,000 | $2.46 Strike: $2.46 | $24,600.00 |
DisclosureSEC source: 0001213900-20-022333 · ownership.xml · derivative · entry 3 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,559 Underlying: Common Stock · 10,000 shares Expires 2022-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2020 Filed Aug 14, 2020 17:15 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 10,000 | $2.46 | $24,600.00 |
DisclosureSEC source: 0001213900-20-022333 · ownership.xml · nonDerivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 17:15 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 10,000 | $18.00 | $180,000.00 |
DisclosureSEC source: 0001213900-20-022333 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,671 F1 · security: These shares sold pursuant to a plan of disposition adopted on June 16, 2020 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 07, 2020 Filed Aug 7, 2020 17:27 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 10,000 | $2.46 Strike: $2.46 | $24,600.00 |
DisclosureSEC source: 0001213900-20-020933 · ownership.xml · derivative · entry 3 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,559 Underlying: Common Stock · 10,000 shares Expires 2022-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2020 Filed Aug 7, 2020 17:27 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 10,000 | $2.46 | $24,600.00 |
DisclosureSEC source: 0001213900-20-020933 · ownership.xml · nonDerivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2020 Filed Aug 7, 2020 17:27 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 10,000 | $17.01 | $170,100.00 |
DisclosureSEC source: 0001213900-20-020933 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,671 F1 · security: These shares sold pursuant to a plan of disposition adopted on June 16, 2020 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 17, 2020 Filed Jul 17, 2020 16:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 8,000 | $2.46 Strike: $2.46 | $19,680.00 |
DisclosureSEC source: 0001213900-20-017818 · ownership.xml · derivative · entry 3 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,559 Underlying: Common Stock · 5,032 shares Expires 2022-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2020 Filed Jul 17, 2020 16:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 8,000 | $2.46 | $19,680.00 |
DisclosureSEC source: 0001213900-20-017818 · ownership.xml · nonDerivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: These shares sold pursuant to a plan of disposition adopted on June 16, 2020 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 16:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 6,667 | $15.00 | $100,005.00 |
DisclosureSEC source: 0001213900-20-017818 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,671 Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 16:15 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 23,302 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001213900-20-014108 · ownership.xml · derivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,559 Underlying: Common Stock · 23,302 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2020 Filed Jun 4, 2020 16:15 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 17,421 | $3.15 | $54,876.15 |
DisclosureSEC source: 0001213900-20-014108 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This Form is being filed to report the exercise of expiring stock options for a total of 23,302 shares by means of a cashless exercise. A cashless exercise is a method of exercising a stock option in which the option holder pays the exercise price using shares the reporting person would have received pursuant to the option exercise. As a result of this cashless exercise, the Reporting Person, on a net basis, acquired ownership of an additional 17,421 shares of common stock. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 17:20 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantStock Option · Derivative | 63,558 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001213900-20-006358 · ownership.xml · derivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,861 Underlying: Common Stock · 63,558 shares Expires 2025-03-11 F1 · derivative.exercise_date: The Stock Option will vest 25% at the end of each quarter starting on 3/31/2020. Read SEC document |
| January 29, 2020 Filed Jan 30, 2020 16:15 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 5,032 | $3.15 Strike: $3.15 | $15,850.80 |
DisclosureSEC source: 0001213900-20-002149 · ownership.xml · derivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,303 Underlying: Common Stock · 5,032 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2020 Filed Jan 30, 2020 16:15 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 5,032 | $3.15 | $15,850.80 |
DisclosureSEC source: 0001213900-20-002149 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2019 Filed Nov 7, 2019 16:24 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 5,000 | $3.15 Strike: $3.15 | $15,750.00 |
DisclosureSEC source: 0001213900-19-022369 · ownership.xml · derivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,335 Underlying: Common Stock · 5,000 shares Expires 2020-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2019 Filed Nov 7, 2019 16:24 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 5,000 | $3.15 | $15,750.00 |
DisclosureSEC source: 0001213900-19-022369 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2019 Filed May 13, 2019 08:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 8,334 | $3.15 Strike: $3.15 | $26,252.10 |
DisclosureSEC source: 0001213900-19-008357 · ownership.xml · derivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,334 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2019 Filed May 13, 2019 08:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 8,334 | $3.15 | $26,252.10 |
DisclosureSEC source: 0001213900-19-008357 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 3, 2019 17:12 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 5,000 | $3.15 Strike: $3.15 | $15,750.00 |
DisclosureSEC source: 0001213900-19-007810 · ownership.xml · derivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,334 Underlying: Common Stock · 5,000 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 3, 2019 17:12 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 5,000 | $3.15 | $15,750.00 |
DisclosureSEC source: 0001213900-19-007810 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 16:26 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 16,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-005250 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,551 F1 · price: The reporting person received a contingent stock grant subject to achievement of the Issuer's 2018 year-end revenue performance goals that were achieved for the year. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 17:16 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Grant · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-003162 · ownership.xml · derivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock grant represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The reporting person received a restricted stock grant that may vest on February 1, 2020, subject to achievement of the Issuer's year-end revenue performance goals. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 15:00 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 5,000 | $3.15 Strike: $3.15 | $15,750.00 |
DisclosureSEC source: 0001213900-19-000132 · ownership.xml · derivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 5,000 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 15:00 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 5,000 | $3.15 | $15,750.00 |
DisclosureSEC source: 0001213900-19-000132 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2018 Filed Aug 10, 2018 17:03 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 15,000 | $3.15 Strike: $3.15 | $47,250.00 |
DisclosureSEC source: 0001213900-18-010721 · ownership.xml · derivative · entry 6 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,669 Underlying: Common · 15,000 shares Expires 2019-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2018 Filed Aug 10, 2018 17:03 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon | 15,000 | $3.15 | $47,250.00 |
DisclosureSEC source: 0001213900-18-010721 · ownership.xml · nonDerivative · entry 5 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2018 Filed Aug 10, 2018 17:03 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 1,000 | $12.05 | $12,050.00 |
DisclosureSEC source: 0001213900-18-010721 · ownership.xml · nonDerivative · entry 4 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,884 Read SEC document |
| August 10, 2018 Filed Aug 10, 2018 17:03 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 1,000 | $12.01 | $12,010.00 |
DisclosureSEC source: 0001213900-18-010721 · ownership.xml · nonDerivative · entry 3 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,884 Read SEC document |
| August 10, 2018 Filed Aug 10, 2018 17:03 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 2,000 | $12.00 | $24,000.00 |
DisclosureSEC source: 0001213900-18-010721 · ownership.xml · nonDerivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,884 Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 17:03 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 784 | $12.00 | $9,408.00 |
DisclosureSEC source: 0001213900-18-010721 · ownership.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,884 Read SEC document |
| March 27, 2018 Filed Mar 29, 2019 16:26 UTC | OptimizeRx Corp OPRX · Entity 213 | ConversionContingent Stock Grant · Derivative | 16,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-005250 · ownership.xml · derivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reporting person received a contingent stock grant subject to achievement of the Issuer's 2018 year-end revenue performance goals that were achieved for the year. F1 · price: The reporting person received a contingent stock grant subject to achievement of the Issuer's 2018 year-end revenue performance goals that were achieved for the year. F1 · derivative.exercise_date: The reporting person received a contingent stock grant subject to achievement of the Issuer's 2018 year-end revenue performance goals that were achieved for the year. F2 · derivative.expiration_date: Not applicable Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 17:16 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Grant · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-001239 · f4020118baker_optimizerx.xml · derivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock grant represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The reporting person received a restricted stock grant that may vest on either February 1, 2019 or February 1, 2020, subject to achievement of the Issuer's year-end revenue performance goals. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| May 11, 2017 Filed May 15, 2017 08:58 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 10,000 | $0.77 | $7,700.00 |
DisclosureSEC source: 0001213900-17-005131 · f4051217baker_optimizer.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 17:01 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001213900-17-003334 · f4033117baker_optimizerx.xml · derivative · entry 2 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 100,000 shares Expires 2022-03-31 F2 · derivative.exercise_date: The Stock Options will vest as to 50% of the shares on September 30, 2017 and 50% of the shares on March 31, 2018. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 17:01 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001213900-17-003334 · f4033117baker_optimizerx.xml · derivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 200,000 shares Expires 2022-03-31 F1 · derivative.exercise_date: The Stock Options were issued based on performance criteria and only vest upon target revenue achieved in 2017. Read SEC document |
| November 14, 2016 Filed Nov 14, 2016 14:14 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 10,000 | $0.85 | $8,500.00 |
DisclosureSEC source: 0001213900-16-018398 · f4111416baker_optimizer.xml · nonDerivative · entry 1 BAKER DOUGLAS P · CIK 0001028775 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.